Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Fibulin-3 As A Diagnostic Biomarker In Patients With Malignant Mesothelioma.

H. Kaya, Melike Demir, M. Taylan, C. Sezgi, A. C. Tanrıkulu, Sureyya Yılmaz, M. Bayram, I. Kaplan, A. Şenyiğit
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND New tumour biomarkers are being intensely investigated for malignant mesothelioma (MM). Fibulin-3 is produced in MM but its role remains uncertain. The aim of this study was to evaluate the validity of measuring serum fibulin-3 in the diagnosis and prognosis of MM. MATERIALS AND METHODS This prospective study was performed on 43 patients and 40 healthy controls who were admitted to our hospital between January 2012 and January 2014. Data from MM patients, including demographic and clinical features, routine laboratory data, levels of serum fibulin-3, and treatment outcomes were defined as potential prognostic factors. The receiver operating characteristic (ROC) curve for fibulin-3 was used to detect the cut-off value with highest sensitivity and specificity. Univariate survival analysis was performed using the Kaplan-Meier method in patients with MM. Afterwards, the possible factors identified with univariate analyses were entered into the cox regression analysis. RESULTS Our results revealed that patients with MM had significantly higher serum levels of fibulin-3 than controls. The results showed that the best cut-off point was 36.6 ng/ml with an AUC (area under the curve)=0.976, sensitivity=93.0% and specificity=90.0. In our study, the initial significant poor prognostic factors were advanced stage, high white blood cell count, high platelet count, high C-reactive protein (p<0.05 for each variable). Later, according to multivariate analysis the results showed only advanced stage as significant parameter (p=0.040). CONCLUSIONS We determined that real use for serum fibulin-3 was not for prognosis but for diagnosis in MM. Also advanced stage was associated with poor MM prognosis.
This paper references
10.1700/1430.15816
Prognostic Factors Affecting Survival in Malignant Pleural Mesothelioma: Analysis of 125 Subjects
B. Komurcuoglu (2014)
10.1097/MCP.0b013e32832b98eb
Serum and pleural fluid biomarkers for mesothelioma
J. Creaney (2009)
10.1053/RMED.2001.1178
Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.
M. Metintas (2001)
Prognostic factors and survival in malignant pleural mesothelioma.
T. van Gelder (1994)
10.1200/JCO.2008.18.9068
Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients.
B. Pierce (2009)
C-reactive protein and malignancy: clinico-pathological association and therapeutic implication.
Chia-Siu Wang (2009)
10.1097/JTO.0b013e3181da78f9
Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer
C. O'Dowd (2010)
10.1378/CHEST.103.4_SUPPLEMENT.373S
Natural history and epidemiology of malignant mesothelioma.
K. Antman (1993)
10.4149/NEO_2011_05_441
Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis.
J. Tong (2011)
10.1158/1541-7786.MCR-09-0207
Fibulin-3 Is Uniquely Upregulated in Malignant Gliomas and Promotes Tumor Cell Motility and Invasion
B. Hu (2009)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
10.1158/1078-0432.CCR-07-1044
Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian Cancer
L. Hefler (2008)
10.1111/j.1440-1843.2007.01187.x
Epidemiology of pleural mesothelioma in a population with non‐occupational asbestos exposure
M. Metintas (2008)
10.1093/jjco/hyq159
Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.
S. Nojiri (2011)
10.1097/00000478-200308000-00001
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
C-reactive protein and malignancy: clinico-pathological association and therapeutic implication.
Wang Cs (2009)
10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
C. Boutin (1993)
10.1016/J.EJCDT.2013.10.004
Role of fibulin-3 in the diagnosis of malignant mesothelioma
M. Agha (2014)
10.1097/CEJ.0b013e3282f0c0a2
US mesothelioma patterns 1973–2002: indicators of change and insights into background rates
M. J. Teta (2008)
10.1016/j.exer.2009.09.018
Focus on molecules: fibulin-3 (EFEMP1).
Y. Zhang (2010)
10.1378/CHEST.122.6.2224
Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.
S. Metintaş (2002)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1159/000321370
A Clinical, Radiographic and Laboratory Evaluation of Prognostic Factors in 363 Patients with Malignant Pleural Mesothelioma
A. C. Tanrıkulu (2010)
10.1016/S0003-4975(99)01038-3
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
10.7314/APJCP.2012.13.11.5735
Clinical characteristics, treatment and survival outcomes in malignant mesothelioma: eighteen years' experience in Turkey.
S. Berk (2012)
10.1158/1078-0432.CCR-10-2817
EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling
Y. Kim (2011)
10.1136/thoraxjnl-2014-205205
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J. Creaney (2014)
10.1245/s10434-009-0790-0
Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1, EFEMP1, a Novel Tumor-Suppressor Gene Detected in Hepatocellular Carcinoma Using Double Combination Array Analysis
Shuji Nomoto (2009)
10.1159/000056289
Incidence of Malignant Pleural Mesothelioma due to Environmental Asbestos Fiber Exposure in the Southeast of Turkey
A. Şenyiğit (2000)
10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
C. Boutin (1993)
10.3892/ijo.2011.1191
Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation.
E. Kim (2012)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)



This paper is referenced by
10.1111/cge.12630
Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases
K. Rai (2016)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
10.1016/j.jtho.2018.08.2036
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
A. Tsao (2018)
10.5772/intechopen.89438
Asbestos-Related Diseases and Blood Biomarkers
A. Franko (2019)
10.1016/j.phrp.2015.11.005
Effect of Repeated Freezing and Thawing on Biomarker Stability in Plasma and Serum Samples
Jae-Eun Lee (2015)
10.18632/oncotarget.14712
Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
Dongxu Pei (2017)
10.2217/bmm-2018-0285
Fibulin-3 as biomarker of malignant mesothelioma.
C. Ledda (2019)
Chronic Inflammation in Malignant Mesothelioma Pathogenesis: Focus on HMGB1 Isoforms and Germline BAP1 Mutations
A. Napolitano (2015)
10.3390/cancers10060203
Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on
C. Ledda (2018)
10.2217/fon.15.271
FBLN-3 as a biomarker of pleural plaques in workers occupationally exposed to carcinogenic fibers: a pilot study.
V. Rapisarda (2015)
10.1016/j.jtho.2016.04.028
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
M. Carbone (2016)
10.18632/oncotarget.25682
The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion
M. Noonan (2018)
Investigating methods regarding diagnostic and prognostic biomarkers for malignant mesothelioma
H. Matsuzaki (2015)
10.1371/journal.pone.0214808
Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals
H. Yang (2019)
10.21037/atm.2017.06.60
Diagnosis and prognosis-review of biomarkers for mesothelioma.
H. H. Sun (2017)
10.1038/s41598-020-77412-4
Overexpression of fibulin-3 in tumor tissue predicts poor survival of malignant mesothelioma patients from hand-spinning asbestos exposed area in eastern China
Z. Jiang (2020)
10.1055/s-0039-1693406
Malignant Mesothelioma: Has Anything Changed?
Roger Y Kim (2019)
10.18632/oncotarget.12707
Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis
Ran Ren (2016)
10.1016/j.envres.2017.03.055
Analysis of fibulin‐3 after exposure to asbestos‐like fibers
V. Rapisarda (2017)
10.1158/1078-0432.CCR-15-1130
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
A. Napolitano (2016)
10.1158/1055-9965.EPI-20-0083
Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network
H. Pass (2020)
10.1038/bjc.2017.22
Prognostication and monitoring of mesothelioma using biomarkers: a systematic review
D. Arnold (2017)
Semantic Scholar Logo Some data provided by SemanticScholar